RELPAX Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Relpax, and what generic alternatives are available?

Relpax is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in RELPAX is eletriptan hydrobromide. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the eletriptan hydrobromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Relpax

A generic version of RELPAX was approved as eletriptan hydrobromide by ZYDUS PHARMS on June 16^th, 2017.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for RELPAX?
What are the global sales for RELPAX?
What is Average Wholesale Price for RELPAX?

Summary for RELPAX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	126
Clinical Trials:	3
Patent Applications:	2,953
Drug Prices:	Drug price information for RELPAX
What excipients (inactive ingredients) are in RELPAX?	RELPAX excipients list
DailyMed Link:	RELPAX at DailyMed

Drug patent expirations by year for RELPAX

Recent Clinical Trials for RELPAX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 1
Pfizer	Phase 1
GlaxoSmithKline	Phase 3

See all RELPAX clinical trials

Pharmacology for RELPAX

Drug Class	Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

Paragraph IV (Patent) Challenges for RELPAX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RELPAX	Tablets	eletriptan hydrobromide	20 mg and 40 mg	021016	1	2010-03-29

US Patents and Regulatory Information for RELPAX

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	RELPAX	eletriptan hydrobromide	TABLET;ORAL	021016-001	Dec 26, 2002	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Upjohn	RELPAX	eletriptan hydrobromide	TABLET;ORAL	021016-002	Dec 26, 2002	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for RELPAX

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	RELPAX	eletriptan hydrobromide	TABLET;ORAL	021016-001	Dec 26, 2002	⤷ Sign Up	⤷ Sign Up
Upjohn	RELPAX	eletriptan hydrobromide	TABLET;ORAL	021016-002	Dec 26, 2002	⤷ Sign Up	⤷ Sign Up
Upjohn	RELPAX	eletriptan hydrobromide	TABLET;ORAL	021016-002	Dec 26, 2002	⤷ Sign Up	⤷ Sign Up
Upjohn	RELPAX	eletriptan hydrobromide	TABLET;ORAL	021016-001	Dec 26, 2002	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for RELPAX

See the table below for patents covering RELPAX around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Mexico	9101606	DERIVADOS DEL INDOL	⤷ Sign Up
Russian Federation	2132683	ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ИНДОЛА В КАЧЕСТВЕ 5HTI АГОНИСТОВ (USE OF INDOLE DERIVATIVES AS 5-HTI-AGONISTS)	⤷ Sign Up
Bulgaria	61975		⤷ Sign Up
Australia	691005		⤷ Sign Up
Germany	9190141		⤷ Sign Up
Japan	2677777		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for RELPAX

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0592438	36/2001	Austria	⤷ Sign Up	PRODUCT NAME: ELETRIPTAN UND DIE PHARMAZEUTISCH VERTRAEGLICHEN SALZE DAVON, EINSCHLIESSLICH DES HYDROBROMIDS; NAT. REGISTRATION NO/DATE: 1-24155 20010801; FIRST REGISTRATION: LI 55218 01, 55218 02 20001214
0592438	SPC/GB01/023	United Kingdom	⤷ Sign Up	PRODUCT NAME: ELETRIPTAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE HYDROBROMIDE SALT; REGISTERED: CH 55218 01 20001214; CH 52218 02 20001214; CH 52218 03 20001214; UK PL 00057/0452 20010212; UK PL 00057/0453 20010212; UK PL 00057/0454 20010212
0592438	02C0013	France	⤷ Sign Up	PRODUCT NAME: ELETRIPTAN HYDROBROMIDE; NAT. REGISTRATION NO/DATE: NL 26625 20011105; FIRST REGISTRATION: LI - IKS 55218 20001214
0592438	C00592438/01	Switzerland	⤷ Sign Up	FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description